Da-Yong Lu* and Bin Xu

School of Life Sciences, Shanghai University, Shanghai, China

*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, China.

Received: April 26, 2021; Published: June 01, 2021

Introduction

  Cancer is the secondary leading disease-induced human mortality worldwide. 60 - 90% cancer mortality is caused by neoplasm metastasis [1-4]. Currently, anticancer drugs are the foremost therapeutic selection because a lot of diversity of tumor origins and drug responses. Several pathways can improve these therapeutic responses and benefiting for bone metastasis treatment;

Future Direction

Finding key genetic or molecular factors that is involving bone metastasis [5].

Development of high-active anticancer or antimetastatic drugs [6-9].

Drug mechanisms and targeting study [10,11].

Herbal medicine may promote human physiological conditions and integrity [12-14].

Personalized medicine is a growing drug selection paradigm that may optimize drug treatment against cancer growth and metastasis [15-25].

Drug combination is an important pathway to promote clinical outcomes yet much efforts should be made to streamline clinical practice [26,27].

Mathematics and computational aids [28-31].

References

1. Lambert AW., et al. “Emerging biological principles of metastasis”. Cell 168 (2017): 670-691.
2. Ahmad AS., et al. “Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960”. British Journal of Cancer 112 (2015): 943-947.
3. Mehlen P and Puisieux A. “Metastasis; a question of life or death”. Nature Reviews Cancer 6 (2006): 449-458.
4. Weidenfeld K and Barkan D. “EMT and stemness in tumor dormacy and outgrowth: Are they intertwined processes?” Frontiers in Oncology 8 (2018): 381.
5. Pantano F., et al. “Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions”. Oncogene 40 (2021): 1284-1299.
6. Lu DY and Che JY. “Bone disease treatments, importance of technical supports”. Acta Scientific Orthopaedics4 (2021): 55-57.
7. Lu DY., et al. “Cancer Metastasis treatments”. Current Drug Therapy1 (2013): 24-29.
8. Lu DY., et al. “Anti-metastatic drug development, work out towards new direction”. Medicinal Chemistry7 (2018): 192-196.
9. Lu DY and Lu TR. “Antimetastatic activities and mechanisms of bisdioxopiperazine compounds”. Anti-Cancer Agent Medicinal Chemistry7 (2010): 564-570.
10. Zhu H., et al. “DJ-1 mediates the resistance of cancer cells to dihydroarteminisinin through cancer cells through reactive oxygen species removal”. Free Radical Biology and Medicine 71 (2014): 121-132.
11. Lu DY., et al. “Development of antimetastatic drugs by targeting tumor sialic acids”. Scientia Pharmaceutica3 (2012): 497-508.
12. Agarwal N., et al. “Natural herbs as anticancer drugs”. International Journal of PharmTech Research3 (2012): 1142-1153.
13. Lu DY., et al. “Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug”. Studies in Natural Products Chemistry 66 (2020): 91-115.
14. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice Palliative Medicine International Journal4 (2019): 125-130.
15. Lu DY., et al. “Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment”. Medical Hypotheses1 (2006): 45-51.
16. Lu DY. “Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics”. Woodhead Publishing, Elsevier, UK (2014).
17. Volm M and Efferth T. “Prediction of cancer drug resistance and implications for personalized medicine”. Frontiers in Oncology (2015): 282.
18. Lu DY., et al. “Anticancer drug sensitivity testing, a historical review and future perspectives”. Current Drug Therapy1 (2015): 44-55.
19. Lu DY and Lu TR. “Drug sensitivity testing, a unique drug selection strategy”. Advances in Biomarker Sciences and Technology 2 (2020): 59-66.
20. Lu DY., et al. “Cancer bioinformatics for update anticancer drug developments and personalized therapeutics”. Reviews on Recent Clinical Trials2 (2017): 101-110.
21. Lu DY., et al. “Pharmacogenetics of cancer therapy: breakthroughs from beyond?” Future Science OA4 (2015): 80.
22. Montero J., et al. “Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy”. Cell 160 (2015): 977-989.
23. Popova AA and Levkin PA. “Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy”. Advanced Therapeutics (2020): 1900100.
24. Hyman DH., et al. “Implementing genome-driven oncology”. Cell 168 (2017): 584-599.
25. Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics and Personalized Medicine2 (2018): 156-163.
26. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry 1 (2017): 21-28.
27. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials3 (2017): 202-211.
28. Franssen L., et al. “A mathematical framework for modeling the metastatic spread of cancer”. Bulletin of Mathematical Biology 81 (2019): 1965-2010.
29. Gerlee P and Johanson M. “Inferring rates of metastatic dissemination using stochastic network models”. PLOS Computational Biology4 (2019): e1006868.
30. Freedman DH. “Hunting for new drugs with AI”. Nature 576 (2019): s49-s53.
31. Lu DY., et al. “Anatomic approaches for cancer metastatic study”. EC Clinical and Experimental Anatomy9 (2020): 32-34.

Citation

Citation: Da-Yong Lu and Bin Xu. “Bone Metastasis Treatments, Major Therapeutic Frontiers".Acta Scientific Orthopaedics 4.7 (2021): 01-02.

Copyright

Copyright: © 2021 Da-Yong Lu and Bin Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.